Is Esperion Therapeutics Stock a Good Investment?
Esperion Therapeutics Investment Advice | ESPR |
- Examine Esperion Therapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Esperion Therapeutics' leadership team and their track record. Good management can help Esperion Therapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Esperion Therapeutics' business and its evolving consumer preferences.
- Compare Esperion Therapeutics' performance and market position to its competitors. Analyze how Esperion Therapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if Esperion Therapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Esperion Therapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Esperion Therapeutics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Esperion Therapeutics is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Unstable | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | High | Details | |
Economic Sensitivity | Almost neglects market trends | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Very Weak | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Possible Manipulator | Details |
Examine Esperion Therapeutics Stock
Researching Esperion Therapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 66.0% of the company shares are held by institutions such as insurance companies. The company recorded a loss per share of 0.28. Esperion Therapeutics had not issued any dividends in recent years. The entity had 1:6 split on the 11th of June 2013.
To determine if Esperion Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Esperion Therapeutics' research are outlined below:
| Esperion Therapeutics generated a negative expected return over the last 90 days | |
| Esperion Therapeutics may become a speculative penny stock | |
| Esperion Therapeutics has high historical volatility and very poor performance | |
| Esperion Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 332.31 M. Net Loss for the year was (51.74 M) with profit before overhead, payroll, taxes, and interest of 217.48 M. | |
| Esperion Therapeutics currently holds about 185.84 M in cash with (23.65 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.79, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Esperion Therapeutics has a very weak financial position based on the latest SEC disclosures | |
| Roughly 66.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from gurufocus.com: Esperion to Participate in 24th Annual Needham Virtual Healthcare Conference |
Esperion Therapeutics Quarterly Cash And Short Term Investments |
|
Esperion Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Esperion Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Esperion Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 20th of February 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 20th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Esperion Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Esperion Therapeutics' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-11-05 | 2024-09-30 | -0.18 | -0.15 | 0.03 | 16 | ||
2025-02-25 | 2024-12-31 | -0.1575 | -0.1013 | 0.0562 | 35 | ||
2023-11-07 | 2023-09-30 | -0.43 | -0.37 | 0.06 | 13 | ||
2015-03-05 | 2014-12-31 | -0.55 | -0.49 | 0.06 | 10 | ||
2013-11-06 | 2013-09-30 | -0.4 | -0.34 | 0.06 | 15 | ||
2015-05-07 | 2015-03-31 | -0.48 | -0.56 | -0.08 | 16 | ||
2016-05-04 | 2016-03-31 | -0.74 | -0.65 | 0.09 | 12 | ||
2022-11-01 | 2022-09-30 | -0.92 | -0.81 | 0.11 | 11 |
Know Esperion Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Esperion Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Esperion Therapeutics backward and forwards among themselves. Esperion Therapeutics' institutional investor refers to the entity that pools money to purchase Esperion Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Nuveen Asset Management, Llc | 2024-12-31 | 3.1 M | Indaba Capital Management, Llc | 2024-12-31 | 3 M | Goldman Sachs Group Inc | 2024-12-31 | 2.8 M | Jpmorgan Chase & Co | 2024-12-31 | 2.5 M | Rhenman Partners Asset Management Ab | 2024-12-31 | 1.9 M | Citadel Advisors Llc | 2024-12-31 | 1.8 M | Bank Of America Corp | 2024-12-31 | 1.6 M | Northern Trust Corp | 2024-12-31 | 1.5 M | Woodline Partners Lp | 2024-12-31 | 1.5 M | Wasatch Advisors Lp | 2024-12-31 | 24.5 M | Blackrock Inc | 2024-12-31 | 14.2 M |
Esperion Therapeutics' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 344.26 M.Market Cap |
|
Esperion Therapeutics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.15) | (0.16) | |
| Return On Capital Employed | 0.56 | 0.59 | |
| Return On Assets | (0.15) | (0.16) | |
| Return On Equity | 0.13 | 0.14 |
Determining Esperion Therapeutics' profitability involves analyzing its financial statements and using various financial metrics to determine if Esperion Therapeutics is a good buy. For example, gross profit margin measures Esperion Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Esperion Therapeutics' profitability and make more informed investment decisions.
Evaluate Esperion Therapeutics' management efficiency
Esperion Therapeutics has return on total asset (ROA) of 0.1237 % which means that it generated a profit of $0.1237 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.6079) %, meaning that it created substantial loss on money invested by shareholders. Esperion Therapeutics' management efficiency ratios could be used to measure how well Esperion Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Esperion Therapeutics' Return On Capital Employed is relatively stable compared to the past year. As of 03/25/2025, Return On Equity is likely to grow to 0.14, while Return On Tangible Assets are likely to drop (0.16). As of 03/25/2025, Other Current Assets is likely to grow to about 19.5 M, while Total Assets are likely to drop slightly above 192.8 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (2.08) | (1.97) | |
| Tangible Book Value Per Share | (2.08) | (1.97) | |
| Enterprise Value Over EBITDA | 74.60 | 78.33 | |
| Price Book Value Ratio | (1.06) | (1.01) | |
| Enterprise Value Multiple | 74.60 | 78.33 | |
| Price Fair Value | (1.06) | (1.01) | |
| Enterprise Value | 564.6 M | 538.4 M |
Effective leadership at Esperion Therapeutics drives its competitive edge in the market. Our analysis focuses on how this translates to financial performance and stock value.
Beta 1.042 |
Basic technical analysis of Esperion Stock
As of the 25th of March, Esperion Therapeutics shows the Standard Deviation of 3.86, variance of 14.92, and Mean Deviation of 2.87. Esperion Therapeutics technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices. Please confirm Esperion Therapeutics information ratio and kurtosis to decide if Esperion Therapeutics is priced favorably, providing market reflects its regular price of 1.69 per share. Please also check Esperion Therapeutics jensen alpha, which is currently at (0.39) to verify the company can sustain itself at a future point.Esperion Therapeutics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Esperion Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Esperion Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Esperion Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Esperion Therapeutics' Outstanding Corporate Bonds
Esperion Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Esperion Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Esperion bonds can be classified according to their maturity, which is the date when Esperion Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| ESPR 4 15 NOV 25 Corp BondUS29664WAB19 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Understand Esperion Therapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Esperion Therapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.08) | |||
| Market Risk Adjusted Performance | 1.55 | |||
| Mean Deviation | 2.87 | |||
| Coefficient Of Variation | (1,050) | |||
| Standard Deviation | 3.86 | |||
| Variance | 14.92 | |||
| Information Ratio | (0.09) | |||
| Jensen Alpha | (0.39) | |||
| Total Risk Alpha | (0.22) | |||
| Treynor Ratio | 1.54 | |||
| Maximum Drawdown | 18.8 | |||
| Value At Risk | (6.51) | |||
| Potential Upside | 5.7 | |||
| Skewness | 0.1369 | |||
| Kurtosis | 1.65 |
| Risk Adjusted Performance | (0.08) | |||
| Market Risk Adjusted Performance | 1.55 | |||
| Mean Deviation | 2.87 | |||
| Coefficient Of Variation | (1,050) | |||
| Standard Deviation | 3.86 | |||
| Variance | 14.92 | |||
| Information Ratio | (0.09) | |||
| Jensen Alpha | (0.39) | |||
| Total Risk Alpha | (0.22) | |||
| Treynor Ratio | 1.54 | |||
| Maximum Drawdown | 18.8 | |||
| Value At Risk | (6.51) | |||
| Potential Upside | 5.7 | |||
| Skewness | 0.1369 | |||
| Kurtosis | 1.65 |
Consider Esperion Therapeutics' intraday indicators
Esperion Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Esperion Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Esperion Therapeutics time-series forecasting models is one of many Esperion Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Esperion Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Esperion Stock media impact
Far too much social signal, news, headlines, and media speculation about Esperion Therapeutics that are available to investors today. That information is available publicly through Esperion media outlets and privately through word of mouth or via Esperion internal channels. However, regardless of the origin, that massive amount of Esperion data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Esperion Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Esperion Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Esperion Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Esperion Therapeutics alpha.
Esperion Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Esperion Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Esperion Therapeutics Corporate Management
| Benjamin JD | General Secretary | Profile | |
| Benjamin MBA | Chief Officer | Profile | |
| Glenn Brame | Chief Officer | Profile | |
| Tiffany MBA | Associate Communications | Profile | |
| Ben MBA | Chief Officer | Profile | |
| Betty Swartz | Chief Officer | Profile |
Additional Tools for Esperion Stock Analysis
When running Esperion Therapeutics' price analysis, check to measure Esperion Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Esperion Therapeutics is operating at the current time. Most of Esperion Therapeutics' value examination focuses on studying past and present price action to predict the probability of Esperion Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Esperion Therapeutics' price. Additionally, you may evaluate how the addition of Esperion Therapeutics to your portfolios can decrease your overall portfolio volatility.